Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone-Refractory Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Early research (Phase 1)Study completedNCT03481816
What this trial is testing

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Who this might be right for
Prostatic NeoplasmsProstatic Cancer
National Cancer Institute (NCI) 18
Not applicableStudy completedNCT03176381
What this trial is testing

Tissue Predictors of Abiraterone Benefit

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tianjin Medical University Second Hospital 110
Testing effectiveness (Phase 2)UnknownNCT02691975
What this trial is testing

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Who this might be right for
Hormone Refractory Prostate CancerMetastatic Prostate Carcinoma
Jiangsu HengRui Medicine Co., Ltd. 197
Early research (Phase 1)Ended earlyNCT05037500
What this trial is testing

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+1 more
Roswell Park Cancer Institute 8
Early research (Phase 1)Study completedNCT02106507
What this trial is testing

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 9
Large-scale testing (Phase 3)Active Not RecruitingNCT05348577
What this trial is testing

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
AstraZeneca 1,035
Testing effectiveness (Phase 2)Ended earlyNCT04631744
What this trial is testing

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 4
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Testing effectiveness (Phase 2)Study completedNCT02020135
What this trial is testing

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Who this might be right for
Prostate Cancer
Progenics Pharmaceuticals, Inc. 9
Testing effectiveness (Phase 2)UnknownNCT00795171
What this trial is testing

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Medical University of Vienna 60
Large-scale testing (Phase 3)Study completedNCT03834506
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,030
Testing effectiveness (Phase 2)Study completedNCT00116155
What this trial is testing

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Cell Genesys
Testing effectiveness (Phase 2)Study completedNCT00082134
What this trial is testing

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Who this might be right for
Hormone-refractory Prostate Cancer
Genzyme, a Sanofi Company 40
Testing effectiveness (Phase 2)Study completedNCT01756638
What this trial is testing

Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Who this might be right for
Prostate Cancer
Janssen Research & Development, LLC 48
Not applicableStudy completedNCT01961843
What this trial is testing

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Massachusetts General Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT00953576
What this trial is testing

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Who this might be right for
Prostate Cancer
Dana-Farber Cancer Institute 11
Early research (Phase 1)Study completedNCT00405210
What this trial is testing

Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

Who this might be right for
Primary DiseaseProstate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 38
Not applicableWithdrawnNCT05245435
What this trial is testing

Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer

Who this might be right for
Prostate Cancer
Medical University of Vienna
Early research (Phase 1)Study completedNCT01353625
What this trial is testing

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Who this might be right for
Glioblastoma MultiformeSquamous Cell Carcinoma of Head and NeckProstate Cancer+3 more
Celgene 118
Next Page